PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has entered into non-binding letter of intent (LOI) with Reliant AI Inc. (“Reliant”), a decision-intelligence company for the life sciences, specializing in generative AI, to collaborate on the development of an artificial-intelligence-powered data analytics platform designed to support clinical trial execution through data-driven insights.
Reliant AI Inc. is a privately held decision-intelligence company powering the next generation of life sciences research with generative AI. Founded by former DeepMind and Google Brain researchers Karl Moritz Hermann and Marc Bellemare, and life sciences expert Richard Schlegel, Reliant AI combines cutting-edge machine learning with deep biomedical expertise The company’s platform automates data-intensive workflows-from systematic literature reviews to commercial success prediction-enabling biopharma teams to make faster, evidence-based decisions.
The proposed platform will improve data-driven decision-making throughout Medicus’ clinical pipeline by combining Reliant’s unique AI technology with Medicus’ clinical, operational, and proprietary datasets. The technology should help trials run more smoothly by allowing for dynamic selection of clinical sites, patient segmentation, and enrollment predictions. The first part of the partnership will be about dynamic site selection for a Teverelix clinical research that is set to start in 2026. This will be backed up by targeted patient-stratification analysis.
“This proposed collaboration is an important strategic step toward selectively using advanced analytics and AI tools to make clinical development more efficient, high-quality, and predictable,” said Dr. Raza Bokhari, Medicus Exec. Chairman & CEO: “By combining AI-enabled modeling with our clinical and pharmacodynamic data, we hope to support more accurate trial execution while keeping our capital discipline. We see this as the foundation for a broader, data-driven clinical execution capability. Our goal is to use these insights to make trials more efficient, help us choose the right patients, and help us make better decisions as our programs move toward late-stage development.”
Applications for Planned Clinical Development
The data analytics platform is expected to be used first for a Medicus-sponsored study planned for the second to fourth quarters of 2026, but it could also be used for a larger, late-stage clinical study planned for 2028 with a development or commercial partner.
The LOI’s first areas of attention are:
Dynamic site selection and re-selection during active patient recruitment
Enrollment simulations and forecasting across geographies
Comparative site-selection strategies to support study planning and partnering discussions
Early pharmacodynamic (PD)-informed patient stratification to optimize inclusion criteria and analytical focus
The platform is expected to use public, commercial, and Medicus proprietary datasets to look at the burden of disease, where it is geographically distributed, and the characteristics of different patient groups. Over time, it will be able to grow into larger feasibility and stratification modules.
Suggested Business Structure
Medicus and Reliant plan to set up their first collaboration as a one-year, milestone-based services engagement with a total financial commitment of no more than $200,000, linked to certain delivery milestones over a 12-month period. This is only if they sign final agreements. The Company will also make all necessary clinical and operational resources available to help with this engagement.
The LOI is not legally binding:
The letter of intent does not form a partnership, joint venture, or agency relationship between the parties and is not legally binding. Final agreements will talk about ownership, intellectual property rights, governance, and the last parameters of the deal, if they ever do. There is no guarantee that a final agreement will be signed or that the planned partnership will go as planned.
Progress on the Skinject Clinical Development Program SKNJCT-003 and SKNJCT-004:
The Company is now doing a Phase 2 clinical investigation for SKNJCT-003 at nine (9) clinical sites in the US. SKNJCT-003 is a Phase 2 clinical study that began randomizing patients in August 2024. It is a double-blind, placebo-controlled, triple-arm study that aims to find a non-invasive way to treat basal cell carcinoma (BCC) of the skin using new, patent-protected dissolvable doxorubicin-containing microneedle arrays (D-MNA). The Company said in December 2025 that it has successfully enrolled ninety (90) patients in the United States for the second phase of the clinical research (SKNJCT-003). The Company plans to share the topline results for SKNJCT-003 in the first quarter of 2026 and have an end of phase 2 (EOP2) meeting with the FDA in the first half of 2026.
In March 2025, the Company said that an interim analysis for SKNJCT-003 showed a good trend, with more than 60% of patients showing clinical clearance. More than half of the 60 patients who were supposed to be in the study were randomly assigned to groups for the interim analysis. The interim analysis results are initial and may or may not align with the final research outcomes.
The Food and Drug Administration (FDA) gave the Company good feedback on its Type C meeting in September 2025, which helped the development of SkinJect. This means that the Company may be able to use the FDA’s 505(b)(2) regulatory pathway to treat BCC of the skin without surgery using dissolvable D-MNA.
The Company treated its first patient in the clinical research (SKNJCT-004) that is currently going on in the United Arab Emirates (UAE) in October 2025. The trial will randomly choose thirty-six (36) patients from six (6) sites in the UAE, with Cleveland Clinic Abu Dhabi (CCAD) as the main investigator. The Company is working with Insights Research firm and Solutions (IROS), a UAE-based contract research firm, to run the clinical study. IROS is one of M42’s portfolio companies.
In November 2025, the Company got all the regulatory and ethical clearances it needed in the UK to expand its ongoing Phase 2 clinical study (SKNJCT-003) that is testing D-MNA as a non-invasive treatment for cutaneous BCC. The Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA), and the Wales Research Ethics Committee (WREC) all gave their clearance. The MHRA gave its approval after a thorough scientific evaluation of the Investigational Medicinal Product Dossier (IMPD) and methodology. The WREC gave the trial a good ethical judgment, and the HRA gave it study-wide governance approval, which showed that it met the standards for U.K. Good Clinical Practice and National Health Service capacity and competency.
Expansion of the Skinject Platform:
In August 2025, the Company said it had signed a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston-based biotech company that is working on creating its own advanced mRNA platform. The two companies will work together to develop thermostable vaccines for infectious diseases.
Acquisition of Antev to Expand the Pipeline
In August 2025, the Company finished buying Antev Limited (“Antev”), a UK-based late-stage biotech company that is working on Teverelix, a next-generation GnRH antagonist that will be the first product on the market for patients with advanced prostate cancer who are at high risk of cardiovascular problems and for patients who have had their first acute urinary retention relapse (AURr) episode due to an enlarged prostate.
Teverelix trifluoroacetate is Antev’s main medication candidate. It is a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Teverelix directly lowers the production of sex hormones without causing an initial spike in testosterone levels, which could lower the risk of heart problems. GnRH agonists, on the other hand, can produce an initial spike in testosterone levels. This process is especially helpful for people who already have heart problems. Teverelix is made as a microcrystalline suspension, which means it releases slowly and has a six-week dose interval. This may help patients stick to their treatment and get better results.
Collaboration between the Gorlin Syndrome Alliance and Patient Access & Advocacy
In October 2025, the Company announced a strategic partnership with the Gorlin Syndrome Alliance (GSA) to improve compassionate access to SkinJect, the Company’s experimental doxorubicin-containing microneedle arrays (D-MNA) for people with Gorlin Syndrome, which is also known as nevoid basal cell carcinoma syndrome.
Medicus and the GSA will work together on the Expanded Access IND Program with the FDA so that patients with many, recurrent, or inoperable BCCs of the skin can get SkinJect under the supervision of a doctor. The goal of the program is to create a framework for greater access while also gathering useful safety and tolerability data from the real world to use in future regulatory filings. It will also better incorporate insights and data from patient-led communities into the planning, monitoring, and long-term growth of SkinJect in this small group of people with a rare disease.
About Reliant AI Inc.
Reliant AI Inc. is a private firm that makes decision-making software that uses generative AI to fuel the next generation of life sciences research. The company’s technology automates procedures that need a lot of data, like systematic literature reviews and predicting commercial success. This lets biopharma teams make choices faster and based on evidence.
Reliant AI was started by Karl Moritz Hermann and Marc Bellemare, who used to work at DeepMind and Google Brain, and Richard Schlegel, who is an expert in life sciences. The company integrates cutting-edge machine learning with profound biomedical knowledge. The company has offices in Berlin, Germany, and Montreal, Canada. Tola Capital and Inovio Capital are two of its investors.
About Medicus Pharma Ltd.
Medicus Pharma Ltd. (Nasdaq:MDCX) is a biotech and life sciences firm that uses precision guidance to speed up the clinical development of new and possibly innovative therapeutic assets. The Company is doing business in several countries on three continents.
